|
17.
|
|
14 p, 892.1 KB |
Discovery of novel DNA methylation biomarkers for non-invasive sporadic breast cancer detection in the Latino population
/
Cappetta, Mónica (Universidad de la República. Departamento de Genética) ;
Fernandez, Lucía (Universidad de la República. Departamento de Genética) ;
Brignoni, Lucía (Universidad de la República. Departamento de Genética) ;
Artagaveytia, Nora (Universidad de la República. Departamento Básico de Medicina) ;
Bonilla, Carolina (University of Bristol. Bristol Medical School) ;
López, Miguel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bertoni, Bernardo (Universidad de la República. Departamento de Genética) ;
Berdasco, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Human diversity is one of the main pitfalls in the development of robust worldwide biomarkers in oncology. Epigenetic variability across human populations is associated with different genetic backgrounds, as well as variable lifestyles and environmental exposures, each of which should be investigated. [...]
2021 -  10.1002/1878-0261.12842
Molecular Oncology, Vol. 15 Núm. 2 (february 2021) , p. 473-486
|
|
|
18.
|
|
16 p, 1.9 MB |
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
/
Ji, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Lin, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shen, S. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Dong, X. (Department of Epidemiology and Biostatistics. School of Public Health. Southeast University) ;
Chen, C. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Li, Y. (Department of Biostatistics. University of Michigan) ;
Zhu, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Huang, H. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Wei, Liangmin (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
He, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Duan, W. (Department of Bioinformatics. School of Biomedical Engineering and Informatics. Nanjing Medical University) ;
Su, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Jiang, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Fan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Guan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
You, D. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shafer, A. (Harvard Medical School) ;
Bjaanæs, Maria Moksnes (Department of Cancer Genetics. Institute for Cancer Research. Oslo University Hospital) ;
Karlsson, A. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Planck, M. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Staaf, J. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Helland, Å. (Institute of Clinical Medicine. University of Oslo) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wei, Y. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Zhang, R. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Chen, F. (Jiangsu Key Lab of Cancer Biomarkers. Prevention and Treatment. Cancer Center. Collaborative Innovation Center for Cancer Personalized Medicine. Nanjing Medical University) ;
Christiani, David C (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non-small-cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early-stage NSCLC patients and evaluated associations between CpG methylation of TRIM27 and overall survival. [...]
2020 - 10.1002/1878-0261.12785
Molecular Oncology, Vol. 14 Núm. 11 (january 2020) , p. 2759-2774
|
|
|
19.
|
|
15 p, 1.9 MB |
Silencing of adaptor protein 32 reduces / receptors expression and impairs gastrointestinal stromal tumors growth
/
Serrano-Candelas, Eva (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ainsua-Enrich, Erola (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Navinés-Ferrer, Arnau (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Macaya, Irati (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona) ;
Serrano, César (Hospital Universitari Vall d'Hebron) ;
Sayós, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martin, Margarita (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Gastrointestinal stromal tumors (s) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most s contain oncogenic (85%) or (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. [...]
2018 - 10.1002/1878-0261.12332
Molecular Oncology, Vol. 12 (june 2018) , p. 1383-1397
|
|
|
20.
|
|
4 p, 147.6 KB |
Towards a Cancer Mission in Horizon Europe
/
Berns, Anton (European Academy of Cancer Sciences) ;
Ringborg, Ulrik (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ;
Baumann, Michael (German Cancer Consortium) ;
Calvo, Fabien (Gustave Roussy Cancer Campus Grand Paris) ;
Eggert, Angelika (Charité - Universitätsmedizin Berlin) ;
Espina, Carolina (International Agency for Research on Cancer) ;
Hanahan, Douglas (Federal Institute of Technology in Lausanne) ;
Lacombe, Denis (EORTC Headquarters) ;
De Lorenzo, Francesco (European Cancer Patient Coalition) ;
Oberst, Simon (Organisation of European Cancer Institutes) ;
Philip, Thierry (Institut Curie) ;
Schüz, Joachim (International Agency for Research on Cancer) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Celis, Julio E. (Danish Cancer Society Research Centre) ;
Universitat Autònoma de Barcelona
2019 - 10.1002/1878-0261.12585
Molecular Oncology, Vol. 13 (october 2019) , p. 2301-2304
|
|
|
21.
|
|
|
22.
|
|
9 p, 351.5 KB |
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS -mutant metastatic colorectal cancer
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Chianese, Chiara (Vall d'Hebron Institut d'Oncologia) ;
Sanz-García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Martinelli, Erica (Università della Campania 'L. Vanvitelli') ;
Noguerido, Alba (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Grasselli, Julieta (Vall d'Hebron Institut d'Oncologia) ;
Cardone, Claudia (Università della Campania 'L. Vanvitelli') ;
Esposito Abate, Riziero (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Martini, Giulia ;
Santos Vivas, Cristina (Universitat de Barcelona) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Garcia, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Mulet, Nuria (Universitat de Barcelona) ;
Maiello, Evaristo (IRCCS Casa Sollievo della Sofferenza) ;
Normanno, Nicola (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Jones, Frederick (Sysmex Inostics) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Ciardello, Fortunato (Università della Campania 'L. Vanvitelli') ;
Salazar, Ramon (Universitat de Barcelona) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS -mutant allele fraction (MAF) in plasma in mCRC. [...]
2019 - 10.1002/1878-0261.12547
Molecular Oncology, Vol. 13 (july 2019) , p. 1827-1835
|
|
|
23.
|
|
9 p, 297.7 KB |
New clinical trial designs in the era of precision medicine
/
Garralda, Elena (Universitat Autònoma de Barcelona) ;
Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ;
Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ;
Braña, Irene (Universitat Autònoma de Barcelona) ;
Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Universitat Autònoma de Barcelona ;
Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557
|
|
|
24.
|
|
19 p, 2.2 MB |
1ε and p120-catenin control Ror2 function in noncanonical Wnt signaling
/
Curto Navarro, Josué (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
del Valle Pérez, Beatriz (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Villarroel, Aida (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Fuertes, Guillem (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Vinyoles, Meritxell (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peña, Raúl (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Garcia de Herreros, Antonio (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut) ;
Dunach, Mireia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Canonical and noncanonical Wnt pathways share some common elements but differ in the responses they evoke. Similar to Wnt ligands acting through the canonical pathway, Wnts that activate the noncanonical signaling, such as Wnt5a, promote Disheveled (Dvl) phosphorylation and its binding to the Frizzled (Fz) Wnt receptor complex. [...]
2018 - 10.1002/1878-0261.12184
Molecular Oncology, Vol. 12, issue 5 (May 2018) , p. 611-629
|
|
|
25.
|
|
10 p, 506.2 KB |
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
/
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Elez, Elena (Hospital Universitari Vall d'Hebron) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ;
Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Saurí Nadal, Tamara (Vall d'Hebron Institut d'Oncologia) ;
Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ;
Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ;
Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Landolfi, Stefania (Universitat Autònoma de Barcelona) ;
Palmer, Héctor G (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272
|
|
|
26.
|
|
10 p, 1.9 MB |
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
/
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Thyparambil, Sheeno (OncoPlex Diagnostics. USA) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Garrido-Castro, Ana (Hospital Universitari Vall d'Hebron) ;
Vilaro, Marta (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Jimenez, José (Vall d'Hebron Institut d'Oncologia) ;
Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ;
Cecchi, Fabiola (OncoPlex Diagnostics. USA) ;
Hoos, William (OncoPlex Diagnostics. USA) ;
Burrows, Jon (OncoPlex Diagnostics. USA) ;
Hembrough, Todd (OncoPlex Diagnostics. USA) ;
Ferreres Piñas, Joan Carles (Hospital Universitari Vall d'Hebron) ;
Pérez-Garcia, José (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V. (Vicente) (Institució Catalana de Recerca i Estudis Avançats) ;
Cortés, Javier (Hospital Universitari Vall d'Hebron) ;
Scaltriti, Maurizio (Memorial Sloan Kettering Cancer Center) ;
Universitat Autònoma de Barcelona
Introduction: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2 treatments. [...]
2016 - 10.1016/j.molonc.2015.09.002
Molecular Oncology, Vol. 10, núm 1 (January 2016) , p. 138-147
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
